EMBRAER (EMBR3) Main Indicators
Basic Data - EMBR3
| Company | EMBRAER |
| Corporate Name | EMBRAER S.A. |
| Registration Status | ATIVO |
| Issuer Status | FASE OPERACIONAL |
| Listing Segment | Novo Mercado |
| Activity | Projeto. desenvolvimento. fabricação. comercialização de aeronaves e sistemas e fornecimento de suporte e serviços de pós-venda. |
| Share | EMBR3 |
| Quote Date | 04/01/2025 |
| Share Type | ON |
| Last Closing | R$ 65.74 |
| Quotation Factor | 1 Share |
| Financial Volume | R$ 358.51 M |
| Last Statement | DFP - 12/31/2024 |
| Sector | Bens Industriais |
| Subsector | Material de Transporte |
| Segment | Material Aeronáutico e de Defesa |
| Participation Indexes | GPTW, IBOVESPA, IBRA, IBRX, IBRX50, ICO2, IGC, IGCT, IGNM, INDX, ITAG, IVBX, MLCX |
| Updated 04/02/2025 | |
Relative Prices - EMBR3
| Price/Earnings | 25.37 |
| Price/SBV | 2.56 |
| Price/Net Sales | 1.37 |
| Price/CFO | 8.80 |
| Price/FCF | 10.74 |
| Price/Total Assets | 0.66 |
| Price/EBIT | 12.90 |
| Price/Working Capital | 3.75 |
| Price/NCAV | -1.18 |
| EV/EBIT | 14.43 |
| EV/EBITDA | 10.66 |
| EV/Net Sales | 1.54 |
| EV/CFO | 9.84 |
| EV/FCF | 12.01 |
| EV/Total Assets | 0.74 |
| Company Market Cap | R$ 48.68 B |
| Enterprise Value | R$ 54.42 B |
| Current Financial Statement Date | 12/31/2024 |
| Current Share Price | R$ 65.74 |
| Share Price Date | 04/01/2025 |
| Dividend Yield | 0.00% |
| Updated 04/02/2025 | |
Income Statement - EMBR3
| Net Revenue | R$ 35.42 B |
| Gross Result | R$ 6.38 B |
| EBIT | R$ 3.77 B |
| Depreciation and Amortization | - R$ 1.33 B |
| EBITDA | R$ 5.10 B |
| Net Profit | R$ 1.92 B |
| Net Profit/Share | R$ 2.59 |
| Updated 02/27/2025 | |
| Net Revenue | R$ 13.74 B |
| Gross Result | R$ 2.54 B |
| EBIT | R$ 1.54 B |
| Depreciation and Amortization | - R$ 435.28 M |
| EBITDA | R$ 1.98 B |
| Net Profit | R$ 263.87 M |
| Profit/Share | R$ 0.36 |
| Updated 02/27/2025 | |
Price and Volume Behavior - EMBR3
| Lowest Price 52 weeks | R$ 30.92 |
| Highest Price 52 weeks | R$ 79.29 |
| Variation 2025 | 13.74% |
| Variation 1 year | 102.96% |
| Variation 2 years(total) | 216.21% |
| Variation 2 years(yearly) | 77.54% |
| Variation 3 years(total) | 336.52% |
| Variation 3 years(yearly) | 63.36% |
| Variation 4 years(total) | 372.95% |
| Variation 4 years(yearly) | 47.43% |
| Variation 5 years(total) | 596.40% |
| Variation 5 years(yearly) | 47.39% |
| Average Daily Volume (3 months) | R$ 418.24 M |
| Updated 04/02/2025 | |
Returns and Margins - EMBR3
| Return on Initial Tangible Capital | 15.66% |
| Return on Initial Invested Capital | 12.72% |
| Pre-Tax Return on Initial Tangible Capital | 23.73% |
| Pre-Tax Return on Initial Invested Capital | 19.27% |
| Return on Initial Shareholder´s Equity | 14.22% |
| Return on Initial Asset | 3.68% |
| Gross Margin | 18.02% |
| Net Margin | 5.42% |
| EBIT Margin | 10.65% |
| EBITDA Margin | 14.41% |
| Initial Asset Turnover | 0.68 |
| Financial Leverage | 3.84 |
| Liabilities/Net Worth | 2.84 |
| Net Debt/EBITDA | 1.13 |
| Updated 02/27/2025 | |
Balance Sheet - EMBR3
| Cash and Cash Equivalents | R$ 9.68 B |
| Total Assets | R$ 73.22 B |
| Short-Term Debt | R$ 704.42 M |
| Long-Term Debt | R$ 14.72 B |
| Gross Debt | R$ 15.43 B |
| Net Debt | R$ 5.75 B |
| Shareholder´s Equity | R$ 19.05 B |
| Share Book Value | R$ 25.72 |
| Common Shares | 740,465,000 |
| Preferred Shares | 0 |
| Total | 740,465,000 |
| Common Shares in Treasury | 5,832,000 |
| Preferred Shares in Treasury | 0 |
| Total in Treasury | 5,832,000 |
| Common Shares (Except Treasury) | 734,633,000 |
| Preferred Shares (Except Treasury) | 0 |
| Total (Except Treasury) | 734,633,000 |
| Updated 02/27/2025 | |
Cash Flow - EMBR3
| Operating Cash Flow | R$ 5.53 B |
| Cash Flow from Investments | - R$ 3.21 B |
| Financing Cash Flow | - R$ 1.91 B |
| Increase (Reduction) in Cash and Equivalents | R$ 1.81 B |
| Updated 02/27/2025 | |
| Operating Cash Flow | R$ 6.24 B |
| Cash Flow from Investments | - R$ 813.56 M |
| Financing Cash Flow | - R$ 1.12 B |
| Increase (Reduction) in Cash and Equivalents | R$ 5.18 B |
| Updated 02/27/2025 | |
Experimental - EMBR3
| CAPEX 3 months | - R$ 108.79 M |
| Free Cash Flow 3 months | R$ 6.13 B |
| CAPEX 12 months | - R$ 999.75 M |
| Free Cash Flow 12 months | R$ 4.53 B |
| Updated 02/27/2025 | |